NASDAQ: CNCE       Concert Pharmaceutic
Last Price Today's Change   Day's Range   Trading Volume
23.84   +0.24 (1.02%)  22.97 - 24.19  235,041


Avg Volume (4 weeks):332,726
4 Weeks Range:17.01 - 26.15
4 Weeks Price Volatility (%):
52 Weeks Range:11.88 - 30.71
52 Weeks Price Volatility (%):
Average Price Target:-


No recent Headlines for this stock.

Business Background

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.

  Be the first to like this.


1907  5559  510  585 

Top 10 Active Counters
 SPY 263.67-6.76 
 BAC 30.55-1.32 
 EEM 47.86-1.65 
 WFT 2.39-0.07 
 TVIX 9.52+1.90 
 XLF 27.66-1.06 
 NVCN 0.114+0.008 
 UVXY 18.68+3.09 
 FB 164.89-4.50 
 GE 13.35-0.53 
Partners & Brokers